You are here: Industry Insights > CARB-X

News List

SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections prnasia
January 11, 2022
SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) Application...
Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections prnasia
November 08, 2021
Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI)...
CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections prnasia
October 19, 2021
Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453...
Vedanta Biosciences gets CARB-X grant to develop anti-infective pharmaceutical-technology
December 09, 2019
Vedanta Biosciences has received a research grant from CARB-X to support the development of an anti-infective to treat hospital-acquired infections by multi-drug resistant organisms (MDRO).
BioVersys Receives CARB-X Award of up to US$ 8.92 Million for Development of Novel Antimicrobial Therapies b3cnewswire
October 30, 2019
BioVersys AG, a privately owned, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in ...
SutroVax Receives CARB-X Award to Group A Streptococcus Infections Vaccine americanpharmaceuticalreview
September 04, 2019
SutroVax has received an award from CARB-X for up to $15 million in non-dilutive funding to develop a universal vaccine to prevent infections caused by Group A Strep bacteria...
ANTABIO Raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-Neg b3cnewswire
October 17, 2017
The Series A Complements Recent CARB-X Grant of up to $8,9 Million
CARB-X announces funding to speed treatments for the world’s deadliest super bugs biospectrumasia
August 02, 2017
Scientists developing promising new antibiotics in India, Ireland, France, Switzerland, the USA and UK are to share up to US$17.6 million.
CARB-X to fund scientists for new antibiotics to treat superbugs expressbpd
July 27, 2017
Bugworks Research India will receive an initial investment of up to $2.6 million